This page shows the latest Zarzio news and features for those working in and with pharma, biotech and healthcare.
In markets outsider the US - where it is known as Zarzio and has been available since 2006 - Sandoz' drug has captured around a 30% share of the Neupogen market.
therapies.”. Biosimilars have been available in Europe since 2006 and Zarxio is already available in more than 40 countries under the brand name Zarzio, where it has captured around 30% of
the brand name Zarzio.
US under the brand name Zarzio.
In the case of Amgen's once-daily white blood cell stimulator Neupogen (filgrastim), however, the drug has now been overtaken by its biosimilar rivals - led by Sandoz' Zarzio - and the
as Zarzio - in Europe in 2009. ... According to the company Zarzio is the leading G-CSF in Europe with a 30 per cent market share.
More from news
Approximately 2 fully matching, plus 8 partially matching documents found.
Establishing an effective customer journey
LEO Innovation Lab and some of its successes to date
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Biosimilars: Getting the flock to market. The biosimilars field is about to become very crowded. Here are some Life tips on how to stand out from the herd. Biosimilars have now been with us for over 10 years. In case you haven't been paying
Zarzio. Omnitrope. Adoport. Adoport International. Mezolar Matrix. Pain portfolio. Mometasone. Shire Pharmaceuticals.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...